SRE Holdings (2980) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
11 Nov, 2025Executive summary
Net sales for FY2025 2Q were ¥8,095 million, down 20.3% YoY, with operating profit at ¥309 million (down 76%) and net income attributable to owners at ¥26 million (down 96%).
The company operates two main segments: AI Cloud & Consulting (AICC) and Life & Property Solutions (L&P), focusing on technology-driven solutions in healthcare, finance, IT, and real estate.
AICC segment showed strong growth, with segment profit up 64% YoY and net sales up 16% YoY; recurring revenue (ARR) reached ¥6,965 million, up 43% YoY.
Generative AI and proprietary data from real business operations are central to the company's competitive advantage and product development.
L & P segment experienced a planned deficit due to project concentration in the second half, with net sales down 28% YoY.
Financial highlights
Gross profit for the period was ¥3,167 million, down from ¥4,457 million YoY.
Ordinary profit was ¥185 million, down 85% YoY.
Basic earnings per share dropped to ¥1.62 from ¥41.24 YoY.
Equity ratio decreased to 37.7% from 44.8% at the previous fiscal year-end.
Average monthly churn rate remained low at 0.4% over the last 12 months.
Outlook and guidance
FY2025 full-year forecast: net sales ¥35 billion (+31% YoY), operating profit ¥4.05 billion (+30% YoY), net income ¥2.22 billion (+31% YoY), and EPS ¥137.88.
AICC segment expected to maintain high growth, with ARR forecast at ¥8.66 billion (+38% YoY).
L & P segment profit and sales are expected to be heavily weighted toward the second half due to seasonality.
No changes to previously announced earnings forecasts.
Dividend forecast is ¥18.0 per share.
Latest events from SRE Holdings
- Record profit and revenue growth driven by AI and real estate, with strong outlook.2980
Q3 202610 Feb 2026 - Sales declined and a net loss was posted, but AI Cloud & Consulting showed strong growth.2980
Q1 20268 Sep 2025 - Strong sales and profit growth driven by segment expansion and Medix acquisition.2980
Q1 20258 Sep 2025 - Double-digit sales and profit growth, boosted by Medix acquisition and segment expansion.2980
Q2 20258 Sep 2025 - Sales up 12.6% but profit down 31.7%; Medix acquisition drives asset and goodwill growth.2980
Q3 20258 Sep 2025 - Strong revenue and profit growth with FY2026 guidance projecting over 30% increases.2980
Q4 20258 Sep 2025